Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort.

Hannah Lewis1, Alexandra Kiss2, Praveen Ramani1

  • 1Department of Pediatrics, Division of Pediatric Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Journal of Child Neurology
|June 2, 2026
PubMed
Summary

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Advances in Child Neurology.

Journal of clinical medicine·2026
Same author

Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches.

Epilepsia·2026
Same author

GAD65 Antibody-Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature.

Journal of child neurology·2026
Same author

Photosensitive infantile spasms in a preterm infant with 4q22.3-q24 deletion involving PPP3CA.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Epilepsy in Epidermal Nevus Syndromes: Review.

Journal of child neurology·2026
Same author

Laser interstitial thermal therapy for refractory epilepsy in children under 2 years: A single-center case series and review of the literature.

Epileptic disorders : international epilepsy journal with videotape·2026

Rituximab shows promise as a first-line therapy for pediatric-onset multiple sclerosis (POMS). This study found it to be well-tolerated and highly effective in preventing relapses and MRI activity in children with POMS.

Area of Science:

  • Pediatric Neurology
  • Immunology
  • Neuroimaging

Background:

  • Pediatric-onset multiple sclerosis (POMS) requires effective long-term therapies.
  • B-cell depletion therapies are increasingly utilized, but data on rituximab as a first-line treatment in POMS are limited.

Purpose of the Study:

  • To evaluate the efficacy and safety of rituximab as a first-line chronic disease-modifying therapy in children with POMS.

Main Methods:

  • Retrospective review of 17 children with POMS treated with rituximab as their initial long-term therapy.
  • Clinical data collection from medical records.
  • Standardized re-review of brain MRI scans by a neuroradiologist to assess T2 lesion counts.

Main Results:

Keywords:
High-efficacy disease-modifying therapypediatric-onset multiple sclerosisrituximab

Related Experiment Videos

Last Updated: Jun 3, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

  • No clinical relapses occurred after rituximab became therapeutically active (≥6 months post-initiation).
  • 94% of patients achieved a composite outcome of clinical and MRI activity-free status.
  • T2 lesion counts remained stable or decreased in all patients compared to baseline.

    • Conclusions:

    • Rituximab demonstrates preliminary support as a well-tolerated, high-efficacy first-line treatment for POMS.
    • Larger prospective studies are warranted to confirm these findings.